BREA, Calif. — (August 2, 2016) —
Today at the 68th AACC Annual Scientific Meeting and Clinical Lab Expo, Beckman Coulter, a global leader in the clinical diagnostic industry, introduces the Beckman Coulter Diagnostics Difference—a unique integrated solution that focuses on achieving laboratory excellence by optimizing operational efficiency and clinical effectiveness. The Beckman Coulter Diagnostics Difference is a synergistic, scalable combination of tools, insights, management systems and process improvements designed to enable healthcare enterprises of every size to manage a range of testing volumes and achieve fast, consistent turnaround times (TAT) at peak workloads. Showcased at booth #2600, these comprehensive solutions target a number of diagnostic disciplines, including laboratory automation, chemistry, immunoassay, hematology, urinalysis and microbiology. In addition, Beckman Coulter offers attendees a preview of products in development, such as a new low-volume hematology analyzer* and a medium-volume chemistry platform**.
“Laboratory test results are among today’s greatest influencers of patient-care decisions,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics. “Because we know that successful healthcare organizations rely on laboratory excellence, we are driven to empower clinical laboratory professionals to meet their quality metrics and financial goals through innovative technology and our unwavering commitment to continuous improvement. This is evident in the Beckman Coulter Diagnostics Difference, which includes personalized expert attention, clinical data management tools, and the Danaher Business System – or DBS – philosophy, which is an integrated set of values and processes designed to yield the highest impact for performance and sustained success.”
“Our clinical laboratory customers tell us that standardizing processes to increase capacity, minimize errors and reduce TATs is critical to their success. They are actively seeking a partner to help them achieve this goal,” said John Nosenzo, SVP global customer operations, Beckman Coulter Diagnostics. “The DBS approach enables us to partner with diagnostic laboratories and their interdisciplinary healthcare associates to build and sustain a culture of continuous improvement across all aspects of patient care.”
In addition to its display of products and services, Beckman Coulter is sponsoring a number of clinically focused workshops, a short course, roundtables, and poster presentations that include best practices and the newest advancements in laboratory technology from industry experts. Additional information can be found on www.beckmancoulter.com/aacc.
Achieving Laboratory Excellence: Debating Winning Strategies for the Clinical
Laboratory in the Current Healthcare Environment
7:00 a.m. to 9:00 a.m. | Wednesday, August 3
Philadelphia Marriott Downtown, Grand Ballroom — Salon D
Moderated by Robert Michel, publisher and editor-in-chief of The Dark Report,
clinical experts debate and share ideas about tactical steps laboratories can take to
build their clinical and economic contributions in different patient-care settings.
Elliot Crouser, M.D.
Associate Professor, Division of Pulmonary, Allergy, Critical Care & Sleep Medicine
The Ohio State University Wexner Medical Center
E. David Crawford, M.D.
Professor of Surgery/Urology/Radiation Oncology
University of Colorado, Denver
Steven H. Wong, Ph.D., DABCC (TC), FACB
Professor of Pathology and Director, Clinical Chemistry and Toxicology
Wake Forest University School of Medicine
1:30 p.m. to 4:00 p.m. | Sunday, July 31
Troubleshooting Clinical Laboratory Errors: Collaborative Case Studies
Dr. Jack Zakowski, Beckman Coulter
Dr. Geoff Baird, University of Washington, Seattle
Dr. Sol Green, BD Preanalytic Systems
12:30 p.m. to 1:30 p.m. | Tuesday, August 2
Hepatitis C Virus: Epidemiology, Testing and Management of Adult Patients
Annette Adelmann, Beckman Coulter
7:30 a.m. to 8:30 a.m. | Wednesday, August 3
Evolving Use of Cardiac Troponins in the ED — Early Rule-In/Rule-Out Protocols and the Use of Significant Deltas
Margot LeClair, Beckman Coulter
9:30 a.m. to 5:00 p.m. | Tuesday or Wednesday, August 2 - 3
Authors will be available at posters from 12:30 p.m. to 1:30 p.m. for discussion with attendees.
Access® Estradiol Sensitive Immunoassay****: Performance of a New Sensitive and Accurate Automated Assay (A-199)
Evaluation of Access TSH (3rd IS) Assay***** with Comparison to Multiple Platforms (A-228)
Commutability – Is it Important and Can Patient Samples be Non-Commutable? Use of CLSI EP14-A3 (A-249)
An Evaluation of the Analytical Performance of the New Beckman Coulter DxC 700 AU Clinical Chemistry System** (B-356)
Enabling Random Access Molecular Testing*** Using Multiple PCR Cells (B-077)
Reliability Proof of the Beckman Coulter DxH 500 System* (A-281)
Multicenter Evaluation Supports Accuracy of the Beckman Coulter Gram-Negative Identification Product with Improved Database for Clinically Significant Bacteria (A-101)
Multicenter Evaluation of Clindamycin MIC Results for Staphylococci Using MicroScan Dried Gram Positive MIC Panels (A-102)
Multicenter Evaluation of Vancomycin MIC Results at 18 Hours for Staphylococci and Enterococci Using MicroScan Dried Overnight Performance Evaluation Device Panel (A-103)